➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Merck
Boehringer Ingelheim
McKinsey

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CABOMETYX

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Cabometyx

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01709435 ↗ Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Active, not recruiting National Cancer Institute (NCI) Phase 1 2012-11-01 This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01716715 ↗ Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2012-11-01 This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether cabozantinib-s-malate or paclitaxel is more effective at treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
NCT01811212 ↗ Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Suspended Exelixis Phase 2 2013-05-01 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
NCT01811212 ↗ Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Suspended National Cancer Institute (NCI) Phase 2 2013-05-01 This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
NCT01822522 ↗ Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus Recruiting National Cancer Institute (NCI) Phase 1 2013-06-01 This phase I trial studies the side effects and best dose of cabozantinib-s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01835145 ↗ Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Active, not recruiting Exelisis Phase 2 2013-07-01 This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma). Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cabozantinib-s-malate works better than temozolomide or dacarbazine in treating patients with melanoma of the eye.
NCT01835145 ↗ Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye Active, not recruiting National Cancer Institute (NCI) Phase 2 2013-07-01 This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma). Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cabozantinib-s-malate works better than temozolomide or dacarbazine in treating patients with melanoma of the eye.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cabometyx

Condition Name

Condition Name for Cabometyx
Intervention Trials
Metastatic Renal Cell Carcinoma 4
Renal Cell Carcinoma 4
Clear Cell Renal Cell Carcinoma 3
Recurrent Renal Cell Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cabometyx
Intervention Trials
Carcinoma 36
Carcinoma, Renal Cell 19
Neoplasms 9
Adenocarcinoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cabometyx

Trials by Country

Trials by Country for Cabometyx
Location Trials
United States 321
Canada 11
Australia 7
Italy 6
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cabometyx
Location Trials
California 15
Washington 12
Pennsylvania 12
Missouri 11
Michigan 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cabometyx

Clinical Trial Phase

Clinical Trial Phase for Cabometyx
Clinical Trial Phase Trials
Phase 3 3
Phase 2 45
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cabometyx
Clinical Trial Phase Trials
Not yet recruiting 36
Recruiting 12
Active, not recruiting 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cabometyx

Sponsor Name

Sponsor Name for Cabometyx
Sponsor Trials
National Cancer Institute (NCI) 24
Exelixis 16
Ipsen 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cabometyx
Sponsor Trials
Other 39
Industry 32
NIH 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
Medtronic
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.